Human T-cell leukemia virus type 1 (HTLV-1) persistently infects humans, and the proviral loads that persist in vivo vary widely among individuals. Elevation in the proviral load is associated with serious HTLV-1-mediated diseases, such as adult T-cell leukemia and HTLV-1-associated myelopathy/tropical spastic paraparesis. However, it remains controversial whether HTLV-1-specific T-cell immunit...

Human T-cell leukemia virus type 1 (HTLV-1) causes adult T-cell leukemia (ATL) and HTLV-1-associated myelopathy/tropical spastic paraparesis in small subsets of HTLV-1 carriers. HTLV-1-specific T-cell responses play critical roles in anti-viral and anti-tumor host defense during HTLV-1 infections. Some HTLV-1 carriers exhibit selective loss or anergy of HTLV-1-specific T-cells at an asymptomati...

CONTEXT: Individuals with HTLV-1 have dysfunctions that directly impact their quality of life. Physiotherapy uses resources help a lot in the treatment these changes. However, questions are asked about which modalities most used and whether they being properly applied. The only certainty is more we know physical therapy individuals HTLV-1, better result used. How, then, this scientific scenario?

The global epidemic of AIDS has become one of the most pressing public health emergencies of this century. Initial reports of AIDS date back to 1981. However, current data suggest that AIDS has existed for at least several decades. While both forms of the human immunodeficiency virus (HIV), type 1 and type 2, are retroviruses capable of causing fatal AIDS, infection with the latter generally re...

OBJECTIVE Hospital and laboratory data indicate that human T-lymphotropic virus type 1 (HTLV-1) is endemic to central Australia, but no community-based studies of its prevalence or disease burden have been reported. We determined the prevalence rates of HTLV-1 infection and of HTLV-1-associated diseases in a remote Indigenous community. SETTING A remote Northern Territory community. DESIGN ...

Infection with human T-lymphotropic virus type 1/2 (HTLV-1/2) is a major health problem. HTLV-1/2 infection is endemic in Chile but representative donor prevalence data are lacking. Data on all blood donors in a large network of Chilean blood centers were examined during 2011-2013. Screening of HTLV-1/2 antibodies were measured by enzyme immunoassay (EIA) at all blood banks. Blood samples with ...